Independent advisers to the FDA endorsed the pill, molnupiravir, in an unusually tight 13-10 vote this week after airing concerns about its low efficacy rate and potential safety risks to pregnant people.
Related posts:
FDA orders J&J contractor Emergent to stop vaccine production during inspection
CDC chief said change on mask guidance not due to public pressure
Supreme Court will hear direct challenge to Roe v. Wade
FDA set to authorize extra Covid vaccine doses for immunocompromised patients
Inside America’s Covid-reporting breakdown
GOP governors embrace Covid cocktails over masks as cases surge
Tensions rise as FDA advisory panel weighs evidence on Pfizer booster
Pfizer and BioNTech ask FDA to approve their Covid-19 vaccine for kids as young as 12
Bad Covid winter brings questions about what’s ‘fully vaccinated’
‘A lot of money on the table’: Fight brews over surprise medical bills
Abortion pill fight could ensnare Biden’s FDA pick
CDC: Vaccinated Americans with a prior infection fared the best during Delta
